The Safety of Rosuvastatin as Used in Common Clinical Practice
- 14 June 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 111 (23) , 3051-3057
- https://doi.org/10.1161/circulationaha.105.555482
Abstract
Background— Statins are currently the mainstay of dyslipidemia management for the primary and secondary prevention of cardiovascular disease. Controversial concerns about the safety of the newly marketed statin rosuvastatin have been raised on the basis of premarketing studies and a few postmarketing reports.Keywords
This publication has 15 references indexed in Scilit:
- Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary DiseaseNew England Journal of Medicine, 2005
- Should rosuvastatin be withdrawn from the market?The Lancet, 2004
- Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III GuidelinesCirculation, 2004
- Dangers of rosuvastatin identified before and after FDA approvalThe Lancet, 2004
- Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary SyndromesNew England Journal of Medicine, 2004
- Evidence-Based Guidelines for Cardiovascular Disease Prevention in WomenCirculation, 2004
- The statin wars: why AstraZeneca must retreatThe Lancet, 2003
- Comparative pharmacology of rosuvastatinAtherosclerosis Supplements, 2003
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialPublished by Elsevier ,2002
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001